The FDA has granted ODD for selumetinib (AZD6244) for the treatment of uveal melanoma. Melanoma of the uveal tract (iris, ciliary body, and choroid) is a rare form of cancer.  Selumetinib is an oral, potent, and selective MEK inhibitor under development by AstraZeneca, headquartered in London, UK.  MEK kinases are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway that are often upregulated in various cancer cells and selumetinib are being investigated in many clinical trials for many types of cancers.  Currently, two clinical trials are being conducted for assessing selumetinib in patients with metastatic uveal melanoma.

 

Related Links:

http://www.astrazeneca.com/Media/Press-releases/Article/20131022–az-initiates-phase-iii-clinical-programme-selumetinib
http://www.cancer.gov/cancertopics/pdq/treatment/intraocularmelanoma/HealthProfessional/page1
http://www.cancer.gov/clinicaltrials/search/results?protocolsearchid=14034155